5

Expression and Role of the TrkA Receptor in Pulmonary Inflammatory Diseases

Véronique Freund-Michel[1,2], Bernard Muller[1,2] and Nelly Frossard[3,4]
[1]*INSERM U1045 "Centre de Recherche Cardio-thoracique de Bordeaux", Bordeaux*
[2]*University Bordeaux Segalen, Bordeaux*
[3]*UMR 7200 CNRS "Laboratoire d'Innovation Thérapeutique", Strasbourg*
[4]*University of Strasbourg, Strasbourg*
France

1. Introduction

The nerve growth factor NGF belongs to the neurotrophin family and was described for the first time more than fifty years ago by Rita Levi-Montalcini and collaborators (Levi-Montalcini et al., 1995; Levi-Montalcini & Hamburger, 1951), who showed its major role in neuronal growth and survival. NGF effects are mediated by activation of two receptor types: the low-affinity p75 receptor for neurotrophins ($p75^{NTR}$) and the high-affinity tropomyosin-related kinase A (TrkA) receptor (Freund-Michel & Frossard, 2008a). The $p75^{NTR}$ receptor belongs to the death receptor family and its activation by NGF at nanomolar concentrations leads either to pro- or anti-apoptotic signalling pathways. The $p75^{NTR}$ receptor is not selective for NGF as it can also bind pro-neurotrophins and the other neurotrophins at the same nanomolar concentrations (Chao, 2003). Inversely, the TrkA receptor is selective for NGF and belongs to the tyrosine-kinase receptor family. Its activation by NGF at picomolar concentrations activates signalling pathways inducing cell proliferation, differentiation and survival in particular through activation of phosphatidylinositol-3 kinase (PI3K), small protein G Ras, phospholipase Cβ (PLCβ) and mitogen-activated protein kinases (MAPK) (Freund-Michel & Frossard, 2008a).

The role of NGF in neuronal growth and survival has been widely studied and led to consider NGF as a promising therapeutic target in several pathologies of the nervous system, in particular neurodegenerative diseases (Prakash et al., 2010). In addition, many studies have suggested that NGF also plays the role of an inflammatory mediator, in particular in the lung (Freund-Michel & Frossard, 2008a). Indeed, numerous sources of NGF have been described in the lung, including infiltrated inflammatory cells, sensory nerves, and many lung structural cells such as fibroblasts, epithelial, endothelial, and

airway or pulmonary vascular smooth muscle cells (Ricci et al., 2004b). These cells have been shown to release more NGF in inflammatory conditions, and may thus participate in increased NGF levels observed in pulmonary inflammatory diseases. In parallel, many studies have shown an active role of NGF in pulmonary inflammation, airway sensory nerve plasticity, airway and vascular hyperreactivity and remodelling (Freund-Michel & Frossard, 2008a). Most of these NGF effects occur through activation of the TrkA receptor, thus highlighting the pivotal role played by this receptor in pulmonary inflammatory diseases.

The aim of the present chapter is to describe the role of the TrkA receptor activated by NGF in pulmonary inflammatory diseases. We will first present the TrkA receptor by describing its discovery, its structure and activity as well as its major signalling pathways. We will then focus on the TrkA receptor in the lung, by describing its pulmonary expression and review its involvement in NGF-mediated effects in the lung. We will describe in particular how the TrkA receptor participates to NGF-induced inflammation, airway and vascular hyperreactivity and remodelling in the lung, focusing on two major pulmonary diseases: asthma and pulmonary hypertension.

2. Presentation of the TrkA receptor

The TrkA receptor belongs to the Trk receptor family, together with TrkB and TrkC receptors. Each Trk receptor binds with a picomolar affinity to a preferred ligand: NGF for TrkA, BDNF (brain-derived neurotrophic factor) and NT-4/5 (neurotrophin-4/5) for TrkB, and NT-3 (neurotrophin-3) for TrkC (Chao, 2003). However, some crosstalks have been described, in particular for NT-3 being able to bind TrkA and TrkB receptors but at higher concentrations (Ryden & Ibanez, 1996).

2.1 Discovery of the TrkA receptor

A proto-oncogene was identified in 1986 by Martin-Zanca and co-workers in human colon carcinomas (Martin-Zanca et al., 1986). This proto-oncogene, resulting from fusion between genes encoding for a tyrosine-kinase domain and a non muscular tropomyosin, was named NTRK or trk for « tropomyosin-related kinase ». Three isoforms were identified and named NTRK1 (or TRKA), NTRK2 (or TRKB) and NTRK3 (or TRKC), with proteins encoded by these genes named Trk (TrkA, TrkB and TrkC) (Martin-Zanca et al., 1986). Expression of Trk proteins was later also detected in thyroid carcinomas and other cancers such as melanomas or breast cancers, as well as in non cancer tissues, in particular in the nervous system (Greco et al., 1997). In 1991, the TrkA protein was identified as the high affinity receptor for NGF (Kaplan et al., 1991a; Klein et al., 1991).

2.2 Structure of the TrkA receptor

The human TrkA receptor is encoded by a gene of 23kb located on chromosome 1q21-q22 (Weier et al., 1995). This gene contains 16 introns of 70bp to 3.3kb and 17 exons of 18 to 394bp (Indo et al., 1997), with the 9 first exons encoding for the extracellular part of the receptor (Metsis, 2001). The TrkA protein contains 790 amino acids with a molecular weight of 140 kDa (Meakin & Shooter, 1992), and is composed of an intracellular domain containing a tyrosine-kinase intrinsic activity, a unique transmembrane helix, and an extracellular

domain dedicated to NGF binding (Wiesmann & de Vos, 2001). This extracellular domain is highly glycosylated, which is essential for activation of TrkA signalling pathways (Friedman & Greene, 1999).

Alternative splicing leads to several isoforms of the TrkA receptor. TrkA I and TrkA II splice variants differ only in the presence or absence of a 6 amino acid sequence. However, even if TrkA II expression is restricted to the nervous system, whereas TrkA I is more ubiquitously expressed (Clary & Reichardt, 1994), no differences in NGF binding or in TrkA function have been identified between these two isoforms (Barker et al., 1993). More recently, a novel hypoxia-regulated TrkA III splice variant has also been described: this isoform is expressed on internal membranes (Tacconelli et al., 2005) and exhibits oncogenic activity (Farina et al., 2009). Finally, a metalloproteinase-dependent cleavage of TrkA extracellular domain has been described, with release of a soluble fragment whose function remains unknown (Cabrera et al., 1996). In parallel, this cleavage induces activation of TrkA intracellular kinase domain, thus providing a TrkA NGF-independent activation, which may contribute to TrkA-dependent effects *in vivo* (Diaz-Rodriguez et al., 1999).

2.3 Activation and signalling pathways of the TrkA receptor

As classically described for other tyrosine-kinase receptors, NGF binds to the extracellular domain of the TrkA receptor and induces its dimerization thereby activating its intracellular tyrosine kinase domain (Kaplan et al., 1991b). Each kinase domain induces phosphorylation of three tyrosine residues (Y670, Y674 and Y675) on the contralateral kinase domain (Mitra, 1991), thus leading to enhancement of kinase activity and further phosphorylation of three other tyrosine residues outside the kinase domain (Y490, Y751 and Y785) (Stephens et al., 1994). These newly phosphorylated tyrosine residues are then recognized by proteins through their SH2 (Src homology domain 2) domains. The adapter protein Shc (Src homology 2-containing protein) interacts with the phosphorylated Y490 residue, phosphatidyl-inositol 3-kinase (PI3K) interacts with the phosphorylated Y751 residue, and phospholipase Cγ (PLCγ) interacts with the phosphorylated Y785 residue, thereby initiating three main signalling pathways that have been widely studied in particular in neuronal cells (Skaper, 2008). However, some recent studies also show activation of these TrkA signalling pathways in non neuronal cells, and in particular in the airways (for reviews: Freund-Michel & Frossard, 2008a; Prakash et al., 2010).

2.3.1 Ras/Raf pathway

Shc intracellular binding to the TrkA receptor leads to phosphorylation of its tyrosine residues and further recognition by the adapter protein Grb-2 (growth factor receptor bound protein-2) through SH3 (Src homology domain 3) domains. Grb-2 then binds to the factor sos (factor son of sevenless) to induce recruitment of the small G protein Ras to the cell membrane and its activation (Segal & Greenberg, 1996). This translocation to the cell membrane enables Ras-induced activation of the Raf kinase and therefore phosphorylation of Raf and activation of the MAPK (mitogen-activated protein kinase) ERK1/2 (extracellular-regulated protein kinase 1/2), leading to activation of survival mechanisms and proliferation (Freund-Michel et al., 2006). Concomitant activation of Rap1, another small

G protein, can potentiate Ras activation and enhance activation of the ERK1/2 pathway (York et al., 2000).

2.3.2 PI3K pathway

PI3K intracellular binding to the TrkA receptor leads to its phosphorylation and activation. PI3K then induces synthesis of phosphatidyl-inositol 3,4-bisphosphate that recruits PDK-1 (phosphoinositide-dependent kinase-1) to the cell membrane and induces activation of PKB (protein-kinase B, also called Akt) (Ashcroft et al., 1999). PKB then leads to activation of gene transcription, either through activation of the small G protein Rac and the MAPK pathway (Kita et al., 1998; Yamaguchi et al., 2001), or through activation of the atypical PKC zeta in a MAPK-independent manner (Wooten et al., 1994). In addition, PKB can lead to activation of proteins belonging to the IAP (inhibitors of apoptosis) family that are involved in cell survival (Wiese et al., 1999). Finally, a Ras-dependent activation of PI3K has also been described, through direct interaction between Ras and PI3K in a complex also containing the adapter protein Gab-1 (Grb2-associated binder-1) after activation of Shc and Grb-2 (Holgado-Madruga et al., 1997; Korhonen et al., 1999).

2.3.3 PLC/PKC pathway

PLCγ is activated by its interaction with the TrkA receptor and its phosphorylation by TrkA intrinsic kinase domains. PLCγ then induces cleavage of phosphatidyl inositol 4,5-bisphosphate into inositol trisphosphate (IP_3) and diacylglycerol (DAG). DAG activates protein-kinase C (PKC) to activate the MAPK pathway, with in particular activation of JNK (c-jun N-terminal kinase) and p38 (Patapoutian & Reichardt, 2001). IP_3 binds to its receptor localized on the endoplasmic reticulum and induces calcium release into the cell cytoplasm, thus contributing to PKC activation (Obermeier et al., 1993).

2.4 Transactivation of the TrkA receptor by G protein-coupled receptors

Neurotrophin-independent activation of Trk receptors, and in particular of the TrkA receptor, has been evidenced in rat neuronal cells after adenosine treatment (Lee & Chao, 2001). Activation of the adenosine A_{2A} receptor, a G protein-coupled receptor (GPCR), induces activation of a kinase belonging to the Src family that is then able to phosphorylate the TrkA receptor and activate the PI3K/PKB pathway (Lee & Chao, 2001; Lee et al., 2002a). This effect has also been evidenced with another GPCR agonist, the pituitary adenylate cyclase-activating peptide (PACAP), being able to induce TrkA transactivation and specific activation of the PI3K/PKB pathway in absence of NGF (Lee et al., 2002b). Since neuroprotective effects of adenosine and PACAP had been previously demonstrated, it has been suggested that this TrkA transactivation mechanism may contribute to these neuroprotective effects through activation of PI3K/PKB (Lee et al., 2002b). However more recent studies suggested that this TrkA transactivation mechanism occurred on newly synthesized TrkA receptors that were not already expressed at the cell membrane (Rajagopal et al., 2004).

2.5 Trafficking of the TrkA receptor

NGF activation of the TrkA receptor expressed on neurons can activate signalling pathways close to the nucleus through a specific mechanism called retrograde transport (Heerssen &

Segal, 2002). Once activated by NGF, the TrkA receptor is internalized, mainly through activation of three mechanisms: clathrine-dependent internalization, caveolae-dependent internalization, or macroendocytosis (Philippidou et al., 2011; Zweifel et al., 2005). All these mechanisms are involved in TrkA internalization and depend i) on the cell type studied, ii) on the concentration of NGF, and iii) on the amplitude of the signal generated by TrkA activation (Zweifel et al., 2005). Once internalized, only a few number of TrkA receptors are transported close to the nucleus, using early endosomes characterized by expression of the small G protein Rab5 and its effector EEA1 (Early endosome antigen 1) (Delcroix et al., 2003). TrkA retrograde transport is dependent upon activation of the PI3K-PKB pathway (Delcroix et al., 2003; Kuruvilla et al., 2000; York et al., 2000). Most of internalized TrkA receptors are either degraded through targeting to lysosomes (Jullien et al., 2002; Saxena et al., 2005) or to the proteasome after ubuquitination (Georgieva et al., 2011; Takahashi et al., 2011), or recycled at the cell membrane (Chen et al., 2005).

3. TrkA expression in the lung

Neurotrophin expression was first described in the central and peripheral nervous systems, participating to nerve growth and survival through activation of Trk and $p75^{NTR}$ receptors. However, neurotrophins and their receptors were later also described in a variety of non-neuronal tissues, and in particular in the lung (Lomen-Hoerth & Shooter, 1995).

3.1 *In vitro* studies

3.1.1 Inflammatory cells

NGF expression, which was first reported in T lymphocytes (Ehrhard et al., 1993a), was later also described in a variety of inflammatory cells including B lymphocytes (Torcia et al., 1996), mast cells (Leon et al., 1994), eosinophils (Solomon et al., 1998) and macrophages (Ricci et al., 2000b). Expression of the TrkA receptor was shown on mast cells (Tam et al., 1997), Th2 lymphocytes (Ehrhard et al., 1993a; Lambiase et al., 1997), B lymphocytes (Torcia et al., 1996), eosinophils (Hahn et al., 2006; Nassenstein et al., 2003; Noga et al., 2002), monocytes and macrophages (Ehrhard et al., 1993b; Otten et al., 1994), and basophils (Burgi et al., 1996).

3.1.2 Airway structural cells

Many airway structural cells such as fibroblasts (Antonelli et al., 2005; Olgart & Frossard, 2001), epithelial cells (Fox et al., 2001; Pons et al., 2001), airway smooth muscle cells (Freund et al., 2002), pulmonary endothelial and vascular smooth muscle cells (Freund-Michel et al., 2009) are sources of NGF (**Fig. 1**). Investigation of TrkA expression on these cells showed TrkA expression in particular on pulmonary fibroblasts (Micera et al., 2001), airway smooth muscle cells (Dagnell et al., 2007; Freund-Michel et al., 2006; Freund-Michel & Frossard, 2008b), airway epithelial cells (Othumpangat et al., 2009), and pulmonary endothelial and vascular smooth muscle cells (Freund-Michel et al., 2010) (**Fig. 1**).

3.2 *In vivo* studies

Expression of TrkA mRNA was initially evidenced in rat and human lung homogenates (Barbacid et al., 1991; Lomen-Hoerth & Shooter, 1995). Expression of TrkA protein was then

shown by immunohistochemistry in isolated human alveolar macrophages (Ricci et al., 2000b), in isolated extrapulmonary arteries (Ricci et al., 2000a), and was later also evidenced on human airway and vascular smooth muscles, on alveolar cells, on airway sensory nerves, as well as on infiltrated inflammatory cells, in particular macrophages, mast cells and lymphocytes (Kassel et al., 2001; Olgart Hoglund et al., 2002; Ricci et al., 2004b). Similar TrkA expression was shown in the mouse lung (Hikawa et al., 2002; Nassenstein et al., 2006).



Fig. 1. Expression of NGF and its receptors in human pulmonary vascular cells

A) NGF protein levels (pg/ml) secreted after 24h by human pulmonary arterial smooth muscle cells (hPASMC) or human pulmonary arterial endothelial cells (hPAEC) in primary culture were assessed by ELISA in the culture cell supernatant. Data are means ± S.E.M. of n=3 experiments performed in triplicates with cells from two different donors. B) TrkA and $p75^{NTR}$ proteins were detected by Western blotting in cultured hPASMC or hPAEC from two different donors (D1 and D2), with rabbit polyclonal anti-human TrkA or $p75^{NTR}$ antibodies as specific protein bands of 140 and 75 kDa respectively. β-Actin probed in the same blots was used to control for protein loading.

4. NGF effects in the lung mediated by activation of the TrkA receptor

NGF is able to stimulate inflammatory cells infiltrated in the bronchial mucosa, promoting in particular their activation and survival in the airways (Freund-Michel & Frossard, 2008a). NGF also displays its role of growth factor on airway nerves, in particular on sensory airway nerves (Hoyle et al., 1998), and is able to stimulate other airway structural cells such as pulmonary fibroblasts or airway smooth muscle cells (Freund-Michel & Frossard, 2008a). Some of these effects involve activation of the TrkA receptor expressed on these cells (**Fig. 2**).



Fig. 2. NGF effects in the lung mediated via activation of the TrkA receptor

NGF-induced activation of the TrkA receptor participates to attraction and activation of inflammatory cells in the lung and may therefore contribute to lung inflammation. The TrkA receptor is also expressed on lung structural cells and participates to NGF-induced effects that may contribute to altered reactivity and remodelling processes existing in pulmonary inflammatory diseases.

4.1 TrkA and inflammatory cells

4.1.1 Mast cells

In vitro, activation of the TrkA receptor by NGF induces granule formation in immature mast cells and therefore contributes to their differentiation (Kim et al., 2008). In addition, NGF is a chemotactic factor for mast cells through both MAPK and PI3K signalling pathways following TrkA activation (Sawada et al., 2000). TrkA activation is also involved in NGF-induced degranulation of mast cells and mediators release such as for example chemokines (Ahamed et al., 2004), or serotonin (Kawamoto et al., 2002). Finally, NGF acts as a key factor to promote mast cell survival through TrkA-induced suppression of apoptosis (Kawamoto et al., 1995). *In vivo*, a correlation between NGF levels in bronchoalveolar lavage (BAL) fluids and the number of mast cells infiltrated in the bronchial mucosa has been evidenced in asthmatic patients after allergenic challenge (Kassel et al., 2001). Expression of TrkA receptors on these mast cells therefore suggests a role for this receptor in NGF-induced attraction and survival of these cells in the lung *in vivo* (Kassel et al., 2001).

4.1.2 Basophils

In vitro, NGF potentiates mediator release from human basophils as well as primes the cells to produce leukotriene C4, and these effects are TrkA-dependent (Burgi et al., 1996). NGF can also modulate IgE-mediated responses in human basophils, and these effects are enhanced on cells from allergic subjects (Sin et al., 2001). However, flow cytometry studies revealed no significant differences in TrkA receptor expression on basophils in this study (Sin et al., 2001).

4.1.3 T and B cells

Although various effects of NGF have been described on T lymphocytes, few studies have investigated the role of the TrkA receptor in these effects. Only one study by Ehrhard and co-workers clearly demonstrates involvement of the TrkA receptor in NGF-induced activation of T lymphocytes *in vitro* (Ehrhard et al., 1994). *In vivo*, NGF effects on T lymphocytes remain controversial, since two studies conducted in a mouse model of asthma failed to show NGF-related effects on T cells (Braun et al., 1998; Path et al., 2002). However, in a transgenic mouse tissue-specifically overexpressing NGF in the lung, increased numbers of T lymphocytes have been shown in the lung after allergenic challenge (Quarcoo et al., 2004). The role of NGF and its TrkA receptor on T lymphocytes in pulmonary inflammatory diseases needs therefore to be further clarified *in vivo*.

NGF has been shown to induce proliferation of B lymphocytes *in vitro*, and this effect occurs through activation of the TrkA receptor and its signalling pathways involving PLCγ, PI3K and MAPK (Melamed et al., 1996). NGF-induced activation of the TrkA receptor also participates to B cell survival through PI3K-dependent activation of PKC zeta (Kronfeld et al., 2002). *In vivo*, in mice lacking TrkA in non-neuronal tissues, all major immune system cell populations were present in normal numbers and distributions, excepted for B lymphocytes, demonstrating that endogenous NGF modulates B cell development through activation of the TrkA receptor (Coppola et al., 2004). Moreover, during allergic airway inflammation in the mouse *in vivo*, NGF contributes to B cell differentiation into plasma cells and activates the TrkA receptor to enhance plasma cell survival and production of immunoglobulins E (Abram et al., 2009).

4.1.4 Eosinophils

In vitro, eosinophil degranulation is promoted by NGF-induced activation of the TrkA receptor, inducing release of inflammatory mediators such as interleukin-4 (Noga et al., 2002). *In vitro* NGF treatment of eosinophils from patients with allergic bronchial asthma increases viability of these cells, and this effect is correlated to increased expression of the TrkA receptor on eosinophils (Nassenstein et al., 2003). In addition, coculture of lung eosinophils with airway epithelial cells resulted in enhanced epithelial neurotrophin production, as well as in prolonged survival of eosinophils (Hahn et al., 2006). Complete inhibition of eosinophil survival in the presence of the TrkA kinase inhibitor K252a confirmed the important role of the TrkA receptor in eosinophil survival (Hahn et al., 2006).

4.1.5 Monocytes / macrophages

NGF induces TrkA activation in monocytes *in vitro* to trigger a respiratory burst, the major component of monocyte cytotoxic activity (Ehrhard et al., 1993b). Activation of the TrkA receptor by NGF also promotes monocytes survival (la Sala et al., 2000). TrkA transactivation mechanisms with GPCR ligands, recently evidenced in monocytes, contribute to pro-inflammatory activities such as for example synthesis of reactive oxygen species (El Zein et al., 2007, 2010). Expression of the TrkA receptor was shown to decrease during *in vitro* differentiation of monocytes to macrophages, suggesting a maturation-dependent regulation of TrkA expression in these cells (Ehrhard et al., 1993b).

NGF was reported to activate macrophages *in vitro* in the process of inflammatory and immune actions, inducing phagocytosis, parasite killing, and production of inflammatory cytokines in a TrkA dependent-manner (Barouch et al., 2001; Susaki et al., 1996). *In vivo*, TrkA expression was reported on human alveolar macrophages (Ricci et al., 2004b; Ricci et al., 2000b), and the TrkA receptor and its binding protein SH2-Bβ participate to activation of alveolar macrophages *in vivo* in a guinea pig model of asthma (Li et al., 2009).

4.1.6 Neutrophils

In a murine model of rhinitis induced by toluene diisocyanate exposure, a massive increased number of neutrophils in the nasal mucosa correlates to increased levels of NGF (Wilfong & Dey, 2004 & 2005). Neutrophil infiltration was inhibited after *in vivo* pre-treatment with the TrkA kinase inhibitor K252a, thus showing the important role of the TrkA receptor on neutrophil attraction in the nasal mucosa (Wilfong & Dey, 2004).

4.2 TrkA and airway structural cells

A role for the TrkA receptor has been evidenced in NGF-induced effects on airway sensory nerves. In particular, NGF induces release of neuropeptides such as substance P by airway neurons, and this effect is TrkA-dependent (de Vries et al., 2006; Dinh et al., 2004). A similar effect has been reported in nasal sensory neurons (Wilfong & Dey, 2004). NGF induces proliferation of airway smooth muscle cells through activation of the TrkA receptor (Freund-Michel et al., 2006). We also showed that NGF multiple stimulation of these cells induce internalization and degradation of the TrkA receptor followed by upregulated re-synthesis of functional TrkA receptors and increased proliferative effect (Freund-Michel & Frossard, 2008b). In ongoing studies, we have recently found that NGF induces proliferation and migration of human pulmonary endothelial and vascular smooth muscle cells *in vitro*,

and that these effects are inhibited by pre-treatment with the TrkA kinase inhibitor K252a, thus suggesting a role for the TrkA receptor in these NGF-mediated effects (Freund-Michel et al., 2009) (**Fig. 3**).



Fig. 3. Involvement of the TrkA receptor in NGF-induced effects on human pulmonary vascular cells.

Effect of NGF (0.1, 10 or 100 ng/ml) after 24h on A) human pulmonary arterial smooth muscle cells (hPASMC) or B) human pulmonary arterial endothelial cells (hPAEC) in primary culture. Cell proliferation was assessed by the BrdU technique and cell migration was evaluated by the Transwell assay. Data are presented as the maximal percentage of increased proliferation or migration compared to untreated control cells. NGF effect was evaluated in the presence or absence of the TrkA kinase inhibitor K252a (100nM, 30min pre-treatment followed by 24h concomitant treatment with NGF). ***: $P<0.001$ versus NGF alone with n=5 independent experiments performed in triplicates with cells from two different donors.

5. Role of the TrkA receptor in pulmonary inflammatory diseases

Circulating NGF levels are increased in human allergic and inflammatory diseases (Bonini et al., 1996). A local increase in NGF secretion has also been evidenced in BAL fluid from asthmatic patients (Kassel et al., 2001; Olgart Hoglund et al., 2002). In addition, our ongoing studies show that pulmonary arteries from patients suffering from pulmonary hypertension secondary to chronic obstructive pulmonary diseases (COPD) secrete more NGF than pulmonary arteries from control donors (Freund-Michel et al., 2010). Asthma and pulmonary hypertension share in common three major features occurring either in airways or in pulmonary arteries: inflammation, tissue hyperreactivity and remodelling (Barnes, 2010; Broide et al., 2011; Hassoun et al., 2009; Humbert, 2010). Several *in vitro* and *in vivo* studies suggest that NGF may play a role in these three physiopathological mechanisms, in particular through activation of the TrkA receptor (**Fig. 4**).



Fig. 4. Potential role of the TrkA receptor in asthma and pulmonary hypertension

In vitro and *in vivo* studies suggest that activation of the TrkA receptor by NGF contributes to inflammation as well as tissue remodelling and altered reactivity, three features occurring in particular in airways and in pulmonary arteries and playing a major role in the physiopathology of asthma and pulmonary hypertension.

5.1 NGF, TrkA and inflammation

5.1.1 Asthma

In a mouse model of asthma, NGF inhibition induced by blocking antibodies administered *in vivo* decreases airway inflammation (Braun et al., 1998; Path et al., 2002). On the contrary, allergen sensitization and challenge in a transgenic mouse tissue specifically overexpressing NGF in the lung displays greater airway inflammation (Path et al., 2002; Quarcoo et al., 2004). *In vivo* administration of a pan-Trk receptor decoy in a mouse model of asthma

reduces interleukin-(IL-)4 and IL-5 cytokine levels (Nassenstein et al., 2006). Substance P is one of the neuropeptides released by airway sensory nerves that participates to neurogenic inflammation in asthma (Quarcoo et al., 2004). *In vivo* treatment with the TrkA kinase inhibitor K252a prevents the increase in substance P observed in a guinea pig model of asthma (de Vries et al., 2006). *In vivo* pre-treatment with TrkA blocking antibodies decreases IL-1β and IL-4 levels in the BAL fluid after allergen sensitization and challenge in the guinea pig (Li et al., 2009). Similar results are observed with TrkA blocking antibodies in a mouse model of asthma (Ni et al., 2010). Altogether, these results show a major role of NGF in airway inflammation through activation of its TrkA receptor.

5.1.2 Pulmonary hypertension

We recently showed that NGF stimulates secretion of inflammatory cytokines such as IL-1β and tumor necrosis factor-α from rat and human pulmonary arteries (Freund-Michel et al., 2010). Moreover, *in vivo* treatment with anti-NGF blocking antibodies in animal models of pulmonary hypertension prevents the increased secretion of these inflammatory cytokines from diseased pulmonary arteries (Freund-Michel et al., unpublished data). Contribution of the TrkA receptor in these mechanisms remains to be determined, but our preliminary data support a role for NGF in the inflammatory mechanisms associated to pulmonary hypertension.

5.2 NGF, TrkA and tissue hyperresponsiveness

5.2.1 Asthma

A role for NGF was reported in airway hyperresponsiveness (AHR) associated to asthma, since pre-treatment with anti-NGF blocking antibodies reduces AHR in various animal models of asthma (Braun et al., 1998; de Vries et al., 2006; Glaab et al., 2003). In addition, AHR is observed after *in vitro* NGF pre-treatment of guinea pig (de Vries et al., 2001), ferret (Wu & Dey, 2006) or human bronchi (Frossard et al., 2005). AHR is reduced *in vivo* after administration of a pan-Trk receptor decoy in a mouse model of asthma (Nassenstein et al., 2006), or of the TrkA kinase inhibitor K252a in a guinea pig model of asthma (de Vries et al., 2006), thus showing involvement of the TrkA receptor in NGF-induced AHR.

5.2.2 Pulmonary hypertension

In the systemic circulation, neurotrophins play a role in the control of vascular tone (Caporali & Emanueli, 2009), and a role for NGF has been suggested in systemic arterial hypertension (Sherer et al., 1998). Neurotrophins and their receptors are expressed on pulmonary arteries (Ricci et al., 2000a), and their expression is increased in the lung of spontaneously hypertensive rats (Ricci et al., 2004a). A role for neurotrophins in the control of the pulmonary arterial tone was recently proposed, through activation of the $p75^{NTR}$ receptor (Xu et al., 2008). BDNF and NT-3 induce relaxation of porcine pulmonary arterial rings, through activation of the endothelial nitric oxide synthase (Meuchel et al., 2011). Suppression of TrkB or TrkC expression via siRNA as well as functional blockade of $p75^{NTR}$ suggest a role of both Trk and $p75^{NTR}$ receptors in these effects (Meuchel et al., 2011). In our ongoing studies in rat or human pulmonary arteries, we show that NGF does not induce rat or human pulmonary arterial contraction or relaxation by itself. However, NGF pre-treatment induces pulmonary arterial hyperresponsiveness to contractile agents such as

phenylephrine or prostaglandin F2α (Freund-Michel et al., 2010). Our preliminary data suggest that this effect may be due in part to activation of the TrkA receptors and increased intracellular calcium concentrations. These mechanisms are in accordance with the preliminary data recently described for BDNF and NT-3 by Prakash and co-workers (Prakash et al., 2010). Altogether, these results therefore suggest that neurotrophins, through activation of both Trk and $p75^{NTR}$ receptors, participate in both endothelial dysfunction and smooth muscle hyperreactivity observed in pulmonary hypertension.

5.3 NGF, TrkA and tissue remodelling

5.3.1 Asthma

Airway remodelling in asthma is characterized by a sub-epithelial fibrosis with an increased proliferation of fibroblasts and a thickening of the basement membrane, hypervascularisation, sensory hyperinnervation, oedema, and hypertrophy and hyperplasia of the smooth muscle layer (Bara et al., 2010). *In vitro*, NGF activates the TrkA receptor to induce migration of pulmonary fibroblasts (Kohyama et al., 2002) and regulation of extracellular matrix synthesis (Khan et al., 2002; Takahashi et al., 2000). These results therefore suggest a role for the TrkA receptor in NGF-induced airway sub-epithelial fibrosis *in vivo* (Hoyle et al., 1998). We also reported that NGF induces proliferation of the airway smooth muscle through activation of the TrkA receptor and may therefore participate to hyperplasia of the smooth muscle layer *in vivo* (Freund-Michel et al., 2006). Activation of the TrkA receptor by NGF also stimulates vascular cells from other origins than the lung to induce migration and proliferation of endothelial cells (Cantarella et al., 2002; Dolle et al., 2005; Lecht et al.,2010 ; Rahbek et al., 2005) as well as migration of vascular smooth muscle cells (Donovan et al., 1995; Kraemer et al., 1999). In addition, NGF stimulates angiogenesis *in vivo* through activation of the TrkA receptor (Cantarella et al., 2002; Caporali & Emanueli, 2009). NGF is also able to stimulate synthesis of angiogenic factors such as vascular endothelial growth factor (VEGF) from various cells through activation of its TrkA receptor (Nakamura et al., 2011). Altogether, these results suggest that activation of the TrkA receptor participates to NGF-mediated hypervascularisation in the lung (Hoyle et al., 1998).

5.3.2 Pulmonary hypertension

Vascular remodelling in pulmonary hypertension is characterized by increased proliferation, decreased apoptosis and increased migration of pulmonary vascular cells (Humbert et al., 2004). NGF-induced activation of the TrkA receptor contributes to migration and proliferation of vascular cells from other origins than the lung and stimulates angiogenesis (see paragraph above). Our recent results show that NGF induces proliferation and migration of pulmonary vascular cells through activation of the TrkA receptor (see paragraph 4.2 and Fig. 3) (Freund-Michel et al., 2010). Therefore, our findings support a role for NGF and its TrkA receptor in pulmonary vascular remodelling in this disease.

6. Therapeutic perspectives and conclusion

In regard of the different results presented in this review, NGF seems to play a major role in altered inflammatory, remodelling and reactivity processes occurring in pulmonary inflammatory diseases such as asthma or pulmonary hypertension. The TrkA receptor is involved in many NGF effects in the lung and targeting NGF or its TrkA receptor may be a new therapeutic perspective in these diseases.

Outside the lung, blockade of NGF is of therapeutic interest in other areas, in particular in pain therapy (Hefti et al., 2006). Humanized monoclonal antibodies against NGF or against TrkA, as well as small molecules acting as TrkA antagonists or as TrkA kinase inhibitors have been developed and are currently under investigation (Ma et al., 2010; Martin et al., 2011; McNamee et al., 2010; Ueda et al., 2010; Watson et al., 2008) **(Fig. 5**). In particular, tanezumab, a recombinant humanized monoclonal antibody against NGF, has been recently tested in clinical trials in osteoarthritic pain and chronic lower back pain and demonstrated good efficacy (Cattaneo, 2010; Lane et al., 2010). Such strategies may be applied in the near future to target NGF or its receptors in pulmonary inflammatory diseases such as asthma or pulmonary hypertension in which NGF and its TrkA receptor play an important role.



Fig. 5. Potential therapeutic strategies to target the TrkA receptor in pulmonary inflammatory diseases.
To trap circulating NGF and prevent its binding to the TrkA receptor, tools such as anti-NGF blocking antibodies or soluble chimeric TrkA receptors have been developed. Other tools have been developed to target the TrkA receptor itself, either by blocking NGF binding to its extracellular part with antagonists or anti-TrkA antibodies, or by blocking TrkA kinase activity with kinase inhibitors.

7. References

Abram, M., Wegmann, M., Fokuhl, V., Sonar, S., Luger, E.O., Kerzel, S., Radbruch, A., Renz, H. & Zemlin, M. (2009). Nerve growth factor and neurotrophin-3 mediate survival of pulmonary plasma cells during the allergic airway inflammation. *Journal of Immunology*, Vol.182, No.8, pp. 4705-4712, ISSN 0022-1767.

Ahamed, J., Venkatesha, R.T., Thangam, E.B. & Ali, H. (2004). C3a enhances nerve growth factor-induced NFAT activation and chemokine production in a human mast cell line, HMC-1. *Journal of Immunology*, Vol.172, No.11, pp. 6961-6968, ISSN 0022-1767.

Antonelli, A., Lapucci, G., Vigneti, E., Bonini, S. & Aloe, L. (2005). Human lung fibroblast response to NGF, IL-1beta, and dexamethsone. *Lung*, Vol.183, No.5, pp. 337-351, ISSN 0341-2040.

Ashcroft, M., Stephens, R.M., Hallberg, B., Downward, J. & Kaplan, D.R. (1999). The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth. *Oncogene*, Vol.18, No.32, pp. 4586-4597, ISSN 0950-9232.

Bara, I., Ozier, A., Tunon de Lara, J.M., Marthan, R. & Berger, P. (2010). Pathophysiology of bronchial smooth muscle remodelling in asthma. *European Respiratory Journal*, Vol.36, No.5, pp. 1174-1184, ISSN 0903-1936.

Barbacid, M., Lamballe, F., Pulido, D. & Klein, R. (1991). The trk family of tyrosine protein kinase receptors. *Biochimica et Biophysica Acta-Cancer Reviews*, Vol.1072, No.2-3, pp. 115-127, ISSN 1879-2561.

Barker, P.A., Lomen-Hoerth, C., Gensch, E.M., Meakin, S.O., Glass, D.J. & Shooter, E.M. (1993). Tissue-specific alternative splicing generates two isoforms of the trkA receptor. *Journal of Biological Chemistry*, Vol.268, No.20, pp. 15150-15157, ISSN 0021-9258.

Barnes, P.J. (2010). New therapies for asthma: is there any progress? *Trends in Pharmacological Sciences*, Vol.31, No.7, pp. 335-343, ISSN 0165-6147.

Barouch, R., Kazimirsky, G., Appel, E. & Brodie, C. (2001). Nerve growth factor regulates TNF-alpha production in mouse macrophages via MAP kinase activation. *Journal of Leukocyte Biology*, Vol.69, No.6, pp. 1019-1026, ISSN 0741-5400.

Bonini, S., Lambiase, A., Bonini, S., Angelucci, F., Magrini, L., Manni, L. & Aloe, L. (1996). Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.93, No.20, pp. 10955-10960, ISSN 0027-8424.

Braun, A., Appel, E., Baruch, R., Herz, U., Botchkarev, V., Paus, R., Brodie, C. & Renz, H. (1998). Role of nerve growth factor in a mouse model of allergic airway inflammation and asthma. *European Journal of Immunology*, Vol.28, No.10, pp. 3240-3251, ISSN 1521-4141.

Broide, D.H., Finkelman, F., Bochner, B.S. & Rothenberg, M.E. (2011). Advances in mechanisms of asthma, allergy, and immunology in 2010. *Journal of Allergy and Clinical Immunology*, Vol.127, No.3, pp. 689-695, ISSN 0105-4538.

Burgi, B., Otten, U.H., Ochensberger, B., Rihs, S., Heese, K., Ehrhard, P.B., Ibanez, C.F. & Dahinden, C.A. (1996). Basophil priming by neurotrophic factors. Activation through the trk receptor. *Journal of Immunology*, Vol.157, No.12, pp. 5582-5588, ISSN 0022-1767.

Cabrera, N., Diaz-Rodriguez, E., Becker, E., Martin-Zanca, D. & Pandiella, A. (1996). TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment. *Journal of Cell Biology*, Vol.132, No.3, pp. 427-436, ISSN 0021-9525.

Cantarella, G., Lempereur, L., Presta, M., Ribatti, D., Lombardo, G., Lazarovici, P., Zappala, G., Pafumi, C. & Bernardini, R. (2002). Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. *FASEB Journal*, Vol.16, No.10, pp. 1307-1309, ISSN 0892-6638.

Caporali, A. & Emanueli, C. (2009). Cardiovascular actions of neurotrophins. *Physiological Reviews*, Vol.89, No.1, pp. 279-308, ISSN 0031-9333.

Cattaneo, A. (2010). Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. *Current Opinion in Molecular Therapeutics*, Vol.12, No.1, pp. 94-106, ISSN 1464-8431.

Chao, M.V. (2003). Neurotrophins and their receptors: a convergence point for many signalling pathways. *Nature Reviews. Neuroscience*, Vol.4, No.4, pp. 299-309, ISSN 1471-0048.

Chen, Z.Y., Ieraci, A., Tanowitz, M. & Lee, F.S. (2005). A novel endocytic recycling signal distinguishes biological responses of Trk neurotrophin receptors. *Molecular Biology of the Cell*, Vol.16, No.12, pp. 5761-5772, ISSN 1059-1524.

Clary, D.O. & Reichardt, L.F. (1994). An alternatively spliced form of the nerve growth factor receptor TrkA confers an enhanced response to neurotrophin 3. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.91, No.23, pp. 11133-11137, ISSN 0027-8424.

Coppola, V., Barrick, C.A., Southon, E.A., Celeste, A., Wang, K., Chen, B., Haddad el, B., Yin, J., Nussenzweig, A., Subramaniam, A. & Tessarollo, L. (2004). Ablation of TrkA function in the immune system causes B cell abnormalities. *Development*, Vol.131, No.20, pp. 5185-5195, ISSN 1011-6370.

Dagnell, C., Kemi, C., Klominek, J., Eriksson, P., Skold, C.M., Eklund, A., Grunewald, J. & Olgart Hoglund, C. (2007). Effects of neurotrophins on human bronchial smooth muscle cell migration and matrix metalloproteinase-9 secretion. *Translational Research*, Vol.150, No.5, pp. 303-310, ISSN 1931-5244.

de Vries, A., Engels, F., Henricks, P.A., Leusink-Muis, T., McGregor, G.P., Braun, A., Groneberg, D.A., Dessing, M.C., Nijkamp, F.P. & Fischer, A. (2006). Airway hyper-responsiveness in allergic asthma in guinea-pigs is mediated by nerve growth factor via the induction of substance P: a potential role for trkA. *Clinical and Experimental Allergy*, Vol.36, No.9, pp. 1192-1200, ISSN 0954-7894.

de Vries, A., van Rijnsoever, C., Engels, F., Henricks, P.A. & Nijkamp, F.P. (2001). The role of sensory nerve endings in nerve growth factor-induced airway hyperresponsiveness to histamine in guinea-pigs. *British Journal of Pharmacology*, Vol.134, No.4, pp. 771-776, ISSN 0007-1188.

Delcroix, J.D., Valletta, J.S., Wu, C., Hunt, S.J., Kowal, A.S. & Mobley, W.C. (2003). NGF signaling in sensory neurons: evidence that early endosomes carry NGF retrograde signals. *Neuron*, Vol.39, No.1, pp. 69-84, ISSN 0896-6273.

Diaz-Rodriguez, E., Cabrera, N., Esparis-Ogando, A., Montero, J.C. & Pandiella, A. (1999). Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms. *European Journal of Neuroscience*, Vol.11, No.4, pp. 1421-1430, ISSN 1460-9568.

Dinh, Q.T., Groneberg, D.A., Peiser, C., Springer, J., Joachim, R.A., Arck, P.C., Klapp, B.F. & Fischer, A. (2004). Nerve growth factor-induced substance P in capsaicin-insensitive vagal neurons innervating the lower mouse airway. *Clinical and Experimental Allergy*, Vol.34, No.9, pp. 1474-1479, ISSN 0954-7894.

Dolle, J.P., Rezvan, A., Allen, F.D., Lazarovici, P. & Lelkes, P.I. (2005). Nerve growth factor-induced migration of endothelial cells. *Journal of Pharmacology and Experimental Therapeutics*, Vol.315, No.3, pp. 1220-1227, ISSN 0022-3565.

Donovan, M.J., Miranda, R.C., Kraemer, R., McCaffrey, T.A., Tessarollo, L., Mahadeo, D., Sharif, S., Kaplan, D.R., Tsoulfas, P., Parada, L. & et al. (1995). Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury. *American Journal of Pathology*, Vol.147, No.2, pp. 309-324, ISSN 0002-9440.

Ehrhard, P.B., Erb, P., Graumann, U. & Otten, U. (1993a). Expression of nerve growth factor and nerve growth factor receptor tyrosine kinase Trk in activated CD4-positive T-cell clones. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.90, No.23, pp. 10984-10988, ISSN 0027-8424.

Ehrhard, P.B., Erb, P., Graumann, U., Schmutz, B. & Otten, U. (1994). Expression of functional trk tyrosine kinase receptors after T cell activation. *Journal of Immunology*, Vol.152, No.6, pp. 2705-2709, ISSN 0022-1767.

Ehrhard, P.B., Ganter, U., Stalder, A., Bauer, J. & Otten, U. (1993b). Expression of functional trk protooncogene in human monocytes. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.90, No.12, pp. 5423-5427, ISSN 0027-8424.

El Zein, N., Badran, B.M. & Sariban, E. (2007). The neuropeptide pituitary adenylate cyclase activating protein stimulates human monocytes by transactivation of the Trk/NGF pathway. *Cellular Signalling*, Vol.19, No.1, pp. 152-162, ISSN 0898-6568.

El Zein, N., D'Hondt, S. & Sariban, E. (2010). Crosstalks between the receptors tyrosine kinase EGFR and TrkA and the GPCR, FPR, in human monocytes are essential for receptors-mediated cell activation. *Cellular Signalling*, Vol.22, No.10, pp. 1437-1447, ISSN 0898-6568.

Farina, A.R., Tacconelli, A., Cappabianca, L., Cea, G., Panella, S., Chioda, A., Romanelli, A., Pedone, C., Gulino, A. & Mackay, A.R. (2009). The alternative TrkAIII splice variant targets the centrosome and promotes genetic instability. *Molecular and Cellular Biology*, Vol.29, No.17, pp. 4812-4830, ISSN 0270-7306.

Fox, A.J., Patel, H.J., Barnes, P.J. & Belvisi, M.G. (2001). Release of nerve growth factor by human pulmonary epithelial cells: role in airway inflammatory diseases. *European Journal of Pharmacology*, Vol.424, No.2, pp. 159-162, ISSN 0014-2999.

Freund-Michel, V., Bertrand, C. & Frossard, N. (2006). TrkA signalling pathways in human airway smooth muscle cell proliferation. *Cellular Signalling*, Vol.18, No.5, pp. 621-627, ISSN 0898-6568.

Freund-Michel, V. & Frossard, N. (2008a). The nerve growth factor and its receptors in airway inflammatory diseases. *Pharmacology and Therapeutics*, Vol.117, No.1, pp. 52-76, ISSN 0163-7258.

Freund-Michel, V. & Frossard, N. (2008b). Overexpression of functional TrkA receptors after internalization in human airway smooth muscle cells. *Biochimica et Biophysica Acta, Molecular and Cellular Research*, Vol.1783, No.10, pp. 1964-1971, ISSN 0167-4889.

Freund-Michel, V., Salagierska, M., Dubois, M., Guibert, C., Courtois, A., Marthan, R. & Muller, B. (2009). Potential role of the nerve growth factor NGF in pulmonary hypertension. European Respiratory Society annual congress, *European Respiratory Journal,* Vol.34, Suppl.53, A4330, ISSN 0903-1936, Vienna, Austria, September 2009.

Freund-Michel, V., Laroumanie, F., Salagierska, M., Dubois, M., Courtois, A., Autissier, M., Guibert, C., Savineau, J.P., Marthan, R. & Muller B. (2010). Nerve growth factor expression and function in pulmonary arterial hypertension. European Respiratory Society annual congress, *European Respiratory Journal,* Vol.36, Suppl.54, P1080, ISSN 0903-1936, Barcelona, Spain, September 2010.

Freund, V., Pons, F., Joly, V., Mathieu, E., Martinet, N. & Frossard, N. (2002). Upregulation of nerve growth factor expression by human airway smooth muscle cells in inflammatory conditions. *European Respiratory Journal*, Vol.20, No.2, pp. 458-463, ISSN 0903-1936.

Friedman, W.J. & Greene, L.A. (1999). Neurotrophin signaling via Trks and p75. *Experimental Cell Research*, Vol.253, No.1, pp. 131-142, ISSN 0014-4827.

Frossard, N., Naline, E., Olgart Hoglund, C., Georges, O. & Advenier, C. (2005). Nerve growth factor is released by IL-1beta and induces hyperresponsiveness of the human isolated bronchus. *European Respiratory Journal*, Vol.26, No.1, pp. 15-20, ISSN 0903-1936.

Georgieva, M.V., de Pablo, Y., Sanchis, D., Comella, J.X. & Llovera, M. (2011). Ubiquitination of TrkA by Nedd4-2 regulates receptor lysosomal targeting and mediates receptor signaling. *Journal of Neurochemistry*, Vol.117, No.3, pp. 479-493, ISSN 0022-3042.

Glaab, T., Hoymann, H.G., Hecht, M., Korolewitz, R., Tschernig, T., Hohlfeld, J.M., Krug, N. & Braun, A. (2003). Effect of anti-nerve growth factor on early and late airway responses in allergic rats. *Allergy*, Vol.58, No.9, pp. 900-904, ISSN 0105-4538.

Greco, A., Miranda, C., Pagliardini, S., Fusetti, L., Bongarzone, I. & Pierotti, M.A. (1997). Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. *Genes, Chromosomes and Cancer*, Vol.19, No.2, pp. 112-123, ISSN 1098-2264.

Hahn, C., Islamian, A.P., Renz, H. & Nockher, W.A. (2006). Airway epithelial cells produce neurotrophins and promote the survival of eosinophils during allergic airway inflammation. *Journal of Allergy and Clinical Immunology*, Vol.117, No.4, pp. 787-794, ISSN 0105-4538.

Hassoun, P.M., Mouthon, L., Barbera, J.A., Eddahibi, S., Flores, S.C., Grimminger, F., Jones, P.L., Maitland, M.L., Michelakis, E.D., Morrell, N.W., Newman, J.H., Rabinovitch, M., Schermuly, R., Stenmark, K.R., Voelkel, N.F., Yuan, J.X. & Humbert, M. (2009). Inflammation, growth factors, and pulmonary vascular remodeling. *Journal of the American College of Cardiology*, Vol.54, No.1 Suppl, pp. S10-19, ISSN 0735-1097.

Heerssen, H.M. & Segal, R.A. (2002). Location, location, location: a spatial view of neurotrophin signal transduction. *Trends in Neurosciences*, Vol.25, No.3, pp. 160-165, ISSN 0166-2236.

Hefti, F.F., Rosenthal, A., Walicke, P.A., Wyatt, S., Vergara, G., Shelton, D.L. & Davies, A.M. (2006). Novel class of pain drugs based on antagonism of NGF. *Trends in Pharmacological Sciences*, Vol.27, No.2, pp. 85-91, ISSN 0165-6147.

Hikawa, S., Kobayashi, H., Hikawa, N., Kusakabe, T., Hiruma, H., Takenaka, T., Tomita, T. & Kawakami, T. (2002). Expression of neurotrophins and their receptors in peripheral lung cells of mice. *Histochemistry and Cell Biology*, Vol.118, No.1, pp. 51-58, ISSN 0948-6143.

Holgado-Madruga, M., Moscatello, D.K., Emlet, D.R., Dieterich, R. & Wong, A.J. (1997). Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase activation and the promotion of cell survival by nerve growth factor. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.94, No.23, pp. 12419-12424, ISSN 0027-8424.

Hoyle, G.W., Graham, R.M., Finkelstein, J.B., Nguyen, K.P., Gozal, D. & Friedman, M. (1998). Hyperinnervation of the airways in transgenic mice overexpressing nerve growth factor. *American Journal of Respiratory Cell and Molecular Biology*, Vol.18, No.2, pp. 149-157, ISSN 1044-1549.

Humbert, M. (2010). Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. *European Respiratory Review*, Vol.19, No.115, pp. 59-63, ISSN 0905-9180.

Humbert, M., Morrell, N.W., Archer, S.L., Stenmark, K.R., MacLean, M.R., Lang, I.M., Christman, B.W., Weir, E.K., Eickelberg, O., Voelkel, N.F. & Rabinovitch, M. (2004). Cellular and molecular pathobiology of pulmonary arterial hypertension. *Journal of the American College of Cardiology*, Vol.43, No.12 Suppl S, pp. 13S-24S, ISSN 0735-1097.

Indo, Y., Mardy, S., Tsuruta, M., Karim, M.A. & Matsuda, I. (1997). Structure and organization of the human TRKA gene encoding a high affinity receptor for nerve growth factor. *Japanese Journal of Human Genetics*, Vol.42, No.2, pp. 343-351, ISSN 0916-8478.

Jullien, J., Guili, V., Reichardt, L.F. & Rudkin, B.B. (2002). Molecular kinetics of nerve growth factor receptor trafficking and activation. *Journal of Biological Chemistry*, Vol.277, No.41, pp. 38700-38708, ISSN 0021-9258.

Kaplan, D.R., Hempstead, B.L., Martin-Zanca, D., Chao, M.V. & Parada, L.F. (1991a). The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. *Science*, Vol.252, No.5005, pp. 554-558, ISSN 0036-8075.

Kaplan, D.R., Martin-Zanca, D. & Parada, L.F. (1991b). Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. *Nature*, Vol.350, No.6314, pp. 158-160, ISSN 0028-0836.

Kassel, O., de Blay, F., Duvernelle, C., Olgart, C., Israel-Biet, D., Krieger, P., Moreau, L., Muller, C., Pauli, G. & Frossard, N. (2001). Local increase in the number of mast cells and expression of nerve growth factor in the bronchus of asthmatic patients after repeated inhalation of allergen at low-dose. *Clinical and Experimental Allergy*, Vol.31, No.9, pp. 1432-1440, ISSN 0954-7894.

Kawamoto, K., Aoki, J., Tanaka, A., Itakura, A., Hosono, H., Arai, H., Kiso, Y. & Matsuda, H. (2002). Nerve growth factor activates mast cells through the collaborative

interaction with lysophosphatidylserine expressed on the membrane surface of activated platelets. *Journal of Immunology*, Vol.168, No.12, pp. 6412-6419, ISSN 0022-1767.

Kawamoto, K., Okada, T., Kannan, Y., Ushio, H., Matsumoto, M. & Matsuda, H. (1995). Nerve growth factor prevents apoptosis of rat peritoneal mast cells through the trk proto-oncogene receptor. *Blood*, Vol.86, No.12, pp. 4638-4644, ISSN 0006-4971.

Khan, K.M., Falcone, D.J. & Kraemer, R. (2002). Nerve growth factor activation of Erk-1 and Erk-2 induces matrix metalloproteinase-9 expression in vascular smooth muscle cells. *Journal of Biological Chemistry*, Vol.277, No.3, pp. 2353-2359, ISSN 0021-9258.

Kim, J.Y., Kim, D.Y. & Ro, J.Y. (2008). Granule formation in NGF-cultured mast cells is associated with expressions of pyruvate kinase type M2 and annexin I proteins. *International Archives of Allergy and Immunology*, Vol.146, No.4, pp. 287-297, ISSN 1018-2438.

Kita, Y., Kimura, K.D., Kobayashi, M., Ihara, S., Kaibuchi, K., Kuroda, S., Ui, M., Iba, H., Konishi, H., Kikkawa, U., Nagata, S. & Fukui, Y. (1998). Microinjection of activated phosphatidylinositol-3 kinase induces process outgrowth in rat PC12 cells through the Rac-JNK signal transduction pathway. *Journal of Cell Science*, Vol.111 (Pt 7), pp. 907-915, ISSN 0021-9533.

Klein, R., Jing, S.Q., Nanduri, V., O'Rourke, E. & Barbacid, M. (1991). The trk proto-oncogene encodes a receptor for nerve growth factor. *Cell*, Vol.65, No.1, pp. 189-197, ISSN 0092-8674.

Kohyama, T., Liu, X., Wen, F.Q., Kobayashi, T., Abe, S., Ertl, R. & Rennard, S.I. (2002). Nerve growth factor stimulates fibronectin-induced fibroblast migration. *Journal of Laboratory and Clinical Medicine*, Vol.140, No.5, pp. 329-335, ISSN 0022-2143.

Korhonen, J.M., Said, F.A., Wong, A.J. & Kaplan, D.R. (1999). Gab1 mediates neurite outgrowth, DNA synthesis, and survival in PC12 cells. *Journal of Biological Chemistry*, Vol.274, No.52, pp. 37307-37314, ISSN 0021-9258.

Kraemer, R., Nguyen, H., March, K.L. & Hempstead, B. (1999). NGF activates similar intracellular signaling pathways in vascular smooth muscle cells as PDGF-BB but elicits different biological responses. *Arteriosclerosis, Thrombosis, and Vascular Biology*, Vol.19, No.4, pp. 1041-1050, ISSN 1079-5642.

Kronfeld, I., Kazimirsky, G., Gelfand, E.W. & Brodie, C. (2002). NGF rescues human B lymphocytes from anti-IgM induced apoptosis by activation of PKCzeta. *European Journal of Immunology*, Vol.32, No.1, pp. 136-143, ISSN 1521-4141.

Kuruvilla, R., Ye, H. & Ginty, D.D. (2000). Spatially and functionally distinct roles of the PI3-K effector pathway during NGF signaling in sympathetic neurons. *Neuron*, Vol.27, No.3, pp. 499-512, ISSN 0896-6273.

la Sala, A., Corinti, S., Federici, M., Saragovi, H.U. & Girolomoni, G. (2000). Ligand activation of nerve growth factor receptor TrkA protects monocytes from apoptosis. *Journal of Leukocyte Biology*, Vol.68, No.1, pp. 104-110, ISSN 0741-5400.

Lambiase, A., Bracci-Laudiero, L., Bonini, S., Bonini, S., Starace, G., D'Elios, M.M., De Carli, M. & Aloe, L. (1997). Human CD4+ T cell clones produce and release nerve growth factor and express high-affinity nerve growth factor receptors. *Journal of Allergy and Clinical Immunology*, Vol.100, No.3, pp. 408-414, ISSN 0105-4538.

Lane, N.E., Schnitzer, T.J., Birbara, C.A., Mokhtarani, M., Shelton, D.L., Smith, M.D. & Brown, M.T. (2010). Tanezumab for the treatment of pain from osteoarthritis of the knee. *New England Journal of Medicine*, Vol.363, No.16, pp. 1521-1531, ISSN 0028-4793.

Lecht, S., Arien-Zakay, H., Wagenstein, Y., Inoue, S., Marcinkiewicz, C., Lelkes, P.I. & Lazarovici, P. (2010) Transient signaling of Erk1/2, Akt and PLCgamma induced by nerve growth factor in brain capillary endothelial cells. *Vascular Pharmacology*, Vol.53, No.3-4, pp. 107-114, ISSN 1537-1891.

Lee, F.S. & Chao, M.V. (2001). Activation of Trk neurotrophin receptors in the absence of neurotrophins. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.98, No.6, pp. 3555-3560, ISSN 0027-8424.

Lee, F.S., Rajagopal, R. & Chao, M.V. (2002a). Distinctive features of Trk neurotrophin receptor transactivation by G protein-coupled receptors. *Cytokine and Growth Factor Reviews*, Vol.13, No.1, pp. 11-17, ISSN 1359-6101.

Lee, F.S., Rajagopal, R., Kim, A.H., Chang, P.C. & Chao, M.V. (2002b). Activation of Trk neurotrophin receptor signaling by pituitary adenylate cyclase-activating polypeptides. *Journal of Biological Chemistry*, Vol.277, No.11, pp. 9096-9102, ISSN 0021-9258.

Leon, A., Buriani, A., Dal Toso, R., Fabris, M., Romanello, S., Aloe, L. & Levi-Montalcini, R. (1994). Mast cells synthesize, store, and release nerve growth factor. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.91, No.9, pp. 3739-3743, ISSN 0027-8424.

Levi-Montalcini, R., Dal Toso, R., della Valle, F., Skaper, S.D. & Leon, A. (1995). Update of the NGF saga. *Journal of the Neurological Sciences*, Vol.130, No.2, pp. 119-127, ISSN 0022-510X.

Levi-Montalcini, R. & Hamburger, V. (1951). Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. *Journal of Experimental Zoology*, Vol.116, No.2, pp. 321-361, ISSN 0022-104X.

Li, L., Kong, L., Fang, X., Jiang, C., Wang, Y., Zhong, Z., Sun, Q., Gu, G., Zheng, D., Meng, R. & Kang, J. (2009). SH2-B beta expression in alveolar macrophages in BAL fluid of asthmatic guinea pigs and its role in NGF-TrkA-mediated asthma. *Respirology*, Vol.14, No.1, pp. 60-68, 1323-7799.

Lomen-Hoerth, C. & Shooter, E.M. (1995). Widespread neurotrophin receptor expression in the immune system and other nonneuronal rat tissues. *Journal of Neurochemistry*, Vol.64, No.4, pp. 1780-1789, ISSN 0022-3042.

Ma, W.Y., Murata, E., Ueda, K., Kuroda, Y., Cao, M.H., Abe, M., Shigemi, K. & Hirose, M. (2010). A synthetic cell-penetrating peptide antagonizing TrkA function suppresses neuropathic pain in mice. *Journal of Pharmacological Sciences*, Vol.114, No.1, pp. 79-84, ISSN 0022-3549.

Martin-Zanca, D., Mitra, G., Long, L.K. & Barbacid, M. (1986). Molecular characterization of the human trk oncogene. *Cold Spring Harbor Symposia on Quantitative Biology*, Vol.51 Pt 2, pp. 983-992, ISSN 0091-7451.

Martin, K.J., Shpiro, N., Traynor, R., Elliott, M. & Arthur, J.S. (2011). Comparison of the specificity of Trk inhibitors in recombinant and neuronal assays. *Neuropharmacology*, Vol.61, No.1-2, pp. 148-155, ISSN 1570-159X.

McNamee, K.E., Burleigh, A., Gompels, L.L., Feldmann, M., Allen, S.J., Williams, R.O., Dawbarn, D., Vincent, T.L. & Inglis, J.J. (2010). Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. *Pain*, Vol.149, No.2, pp. 386-392, ISSN 0304-3959.

Meakin, S.O. & Shooter, E.M. (1992). The nerve growth factor family of receptors. *Trends in Neurosciences*, Vol.15, No.9, pp. 323-331, ISSN 0166-2236.

Melamed, I., Kelleher, C.A., Franklin, R.A., Brodie, C., Hempstead, B., Kaplan, D. & Gelfand, E.W. (1996). Nerve growth factor signal transduction in human B lymphocytes is mediated by gp140trk. *European Journal of Immunology*, Vol.26, No.9, pp. 1985-1992, ISSN 1521-4141.

Metsis, M. (2001). Genes for neurotrophic factors and their receptors: structure and regulation. *Cellular and Molecular Life Sciences*, Vol.58, No.8, pp. 1014-1020, ISSN 1420-682X.

Meuchel, L.W., Thompson, M.A., Cassivi, S.D., Pabelick, C.M. & Prakash, Y.S. (2011). Neurotrophins induce nitric oxide generation in human pulmonary artery endothelial cells. *Cardiovascular Research*, 2011 May 18, [Epub ahead of print], ISSN 0008-6363.

Micera, A., Vigneti, E., Pickholtz, D., Reich, R., Pappo, O., Bonini, S., Maquart, F.X., Aloe, L. & Levi-Schaffer, F. (2001). Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.98, No.11, pp. 6162-6167, ISSN 0027-8424.

Mitra, G. (1991). Mutational analysis of conserved residues in the tyrosine kinase domain of the human trk oncogene. *Oncogene*, Vol.6, No.12, pp. 2237-2241, ISSN 0950-9232.

Nakamura, K., Tan, F., Li, Z. & Thiele, C.J. (2011). NGF activation of TrkA induces vascular endothelial growth factor expression via induction of hypoxia-inducible factor-1alpha. *Molecular and Cellular Neurosciences*, Vol.46, No.2, pp. 498-506, ISSN 1044-7431.

Nassenstein, C., Braun, A., Erpenbeck, V.J., Lommatzsch, M., Schmidt, S., Krug, N., Luttmann, W., Renz, H. & Virchow, J.C., Jr. (2003). The neurotrophins nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 are survival and activation factors for eosinophils in patients with allergic bronchial asthma. *Journal of Experimental Medicine*, Vol.198, No.3, pp. 455-467, ISSN 0022-1007.

Nassenstein, C., Dawbarn, D., Pollock, K., Allen, S.J., Erpenbeck, V.J., Spies, E., Krug, N. & Braun, A. (2006). Pulmonary distribution, regulation, and functional role of Trk receptors in a murine model of asthma. *Journal of Allergy and Clinical Immunology*, Vol.118, No.3, pp. 597-605, ISSN 0105-4538.

Ni, X., Li, X., Fang, X., Li, N., Cui, W. & Zhang, B. (2010). NGF/TrkA-mediated Kidins220/ARMS signaling activated in the allergic airway challenge in mice. *Annals of Allergy, Asthma, and Immunology*, Vol.105, No.4, pp. 299-306, ISSN 1081-1206.

Noga, O., Englmann, C., Hanf, G., Grutzkau, A., Guhl, S. & Kunkel, G. (2002). Activation of the specific neurotrophin receptors TrkA, TrkB and TrkC influences the function of eosinophils. *Clinical and Experimental Allergy*, Vol.32, No.9, pp. 1348-1354, ISSN 0954-7894.

Obermeier, A., Halfter, H., Wiesmuller, K.H., Jung, G., Schlessinger, J. & Ullrich, A. (1993). Tyrosine 785 is a major determinant of Trk-substrate interaction. *EMBO Journal*, Vol.12, No.3, pp. 933-941, ISSN 0261-4189.

Olgart, C. & Frossard, N. (2001). Human lung fibroblasts secrete nerve growth factor: effect of inflammatory cytokines and glucocorticoids. *European Respiratory Journal*, Vol.18, No.1, pp. 115-121, ISSN 0903-1936.

Olgart Hoglund, C., de Blay, F., Oster, J.P., Duvernelle, C., Kassel, O., Pauli, G. & Frossard, N. (2002). Nerve growth factor levels and localisation in human asthmatic bronchi. *European Respiratory Journal*, Vol.20, No.5, pp. 1110-1116, ISSN 0903-1936.

Othumpangat, S., Gibson, L.F., Samsell, L. & Piedimonte, G. (2009). NGF is an essential survival factor for bronchial epithelial cells during respiratory syncytial virus infection. *PLoS ONE*, Vol.4, No.7, pp. e6444, ISSN 1932-6203.

Otten, U., Scully, J.L., Ehrhard, P.B. & Gadient, R.A. (1994). Neurotrophins: signals between the nervous and immune systems. *Progress in Brain Research*, Vol.103, pp. 293-305, ISSN 0079-6123.

Patapoutian, A. & Reichardt, L.F. (2001). Trk receptors: mediators of neurotrophin action. *Current Opinion in Neurobiology*, Vol.11, No.3, pp. 272-280, ISSN 0959-4388.

Path, G., Braun, A., Meents, N., Kerzel, S., Quarcoo, D., Raap, U., Hoyle, G.W., Nockher, W.A. & Renz, H. (2002). Augmentation of allergic early-phase reaction by nerve growth factor. *American Journal of Respiratory and Critical Care Medicine*, Vol.166, No.6, pp. 818-826, ISSN 073-449X.

Philippidou, P., Valdez, G., Akmentin, W., Bowers, W.J., Federoff, H.J. & Halegoua, S. (2011). Trk retrograde signaling requires persistent, Pincher-directed endosomes. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.108, No.2, pp. 852-857, ISSN 0027-8424.

Pons, F., Freund, V., Kuissu, H., Mathieu, E., Olgart, C. & Frossard, N. (2001). Nerve growth factor secretion by human lung epithelial A549 cells in pro- and anti-inflammatory conditions. *European Journal of Pharmacology*, Vol.428, No.3, pp. 365-369, ISSN 0014-2999.

Prakash, Y., Thompson, M.A., Meuchel, L., Pabelick, C.M., Mantilla, C.B., Zaidi, S. & Martin, R.J. (2010). Neurotrophins in lung health and disease. *Expert Review of Respiratory Medicine*, Vol.4, No.3, pp. 395-411, ISSN 1747-6348.

Quarcoo, D., Schulte-Herbruggen, O., Lommatzsch, M., Schierhorn, K., Hoyle, G.W., Renz, H. & Braun, A. (2004). Nerve growth factor induces increased airway inflammation via a neuropeptide-dependent mechanism in a transgenic animal model of allergic airway inflammation. *Clinical and Experimental Allergy*, Vol.34, No.7, pp. 1146-1151, ISSN 0954-7894.

Rahbek, U.L., Dissing, S., Thomassen, C., Hansen, A.J. & Tritsaris, K. (2005). Nerve growth factor activates aorta endothelial cells causing PI3K/Akt- and ERK-dependent

migration. *Pflugers Archiv (European Journal of Physiology)*, Vol.450, No.5, pp. 355-361, ISSN 0031-6768.

Rajagopal, R., Chen, Z.Y., Lee, F.S. & Chao, M.V. (2004). Transactivation of Trk neurotrophin receptors by G-protein-coupled receptor ligands occurs on intracellular membranes. *Journal of Neuroscience*, Vol.24, No.30, pp. 6650-6658, ISSN 0270-6474.

Ricci, A., Bronzetti, E., Mannino, F., Felici, L., Terzano, C. & Mariotta, S. (2004a). Elevated neurotrophin and neurotrophin receptor expression in spontaneously hypertensive rat lungs. *Growth Factors*, Vol.22, No.3, pp. 195-205, ISSN 0897-7194.

Ricci, A., Felici, L., Mariotta, S., Mannino, F., Schmid, G., Terzano, C., Cardillo, G., Amenta, F. & Bronzetti, E. (2004b). Neurotrophin and neurotrophin receptor protein expression in the human lung. *American Journal of Respiratory Cell and Molecular Biology*, Vol.30, No.1, pp. 12-19, ISSN 1044-1549.

Ricci, A., Greco, S., Amenta, F., Bronzetti, E., Felici, L., Rossodivita, I., Sabbatini, M. & Mariotta, S. (2000a). Neurotrophins and neurotrophin receptors in human pulmonary arteries. *Journal of Vascular Research*, Vol.37, No.5, pp. 355-363, ISSN 1018-1172.

Ricci, A., Greco, S., Mariotta, S., Felici, L., Amenta, F. & Bronzetti, E. (2000b). Neurotrophin and neurotrophin receptor expression in alveolar macrophages: an immunocytochemical study. *Growth Factors*, Vol.18, No.3, pp. 193-202, ISSN 0897-7194.

Ryden, M. & Ibanez, C.F. (1996). Binding of neurotrophin-3 to p75LNGFR, TrkA, and TrkB mediated by a single functional epitope distinct from that recognized by trkC. *Journal of Biological Chemistry*, Vol.271, No.10, pp. 5623-5627, ISSN 0021-9258.

Sawada, J., Itakura, A., Tanaka, A., Furusaka, T. & Matsuda, H. (2000). Nerve growth factor functions as a chemoattractant for mast cells through both mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways. *Blood*, Vol.95, No.6, pp. 2052-2058, ISSN 0006-4971.

Saxena, S., Howe, C.L., Cosgaya, J.M., Steiner, P., Hirling, H., Chan, J.R., Weis, J. & Kruttgen, A. (2005). Differential endocytic sorting of p75NTR and TrkA in response to NGF: a role for late endosomes in TrkA trafficking. *Molecular and Cellular Neurosciences*, Vol.28, No.3, pp. 571-587, ISSN 1044-7431.

Segal, R.A. & Greenberg, M.E. (1996). Intracellular signaling pathways activated by neurotrophic factors. *Annual Review of Neuroscience*, Vol.19, pp. 463-489, ISSN 0743-4634.

Sherer, T.B., Neff, P.S., Hankins, G.R. & Tuttle, J.B. (1998). Mechanisms of increased NGF production in vascular smooth muscle of the spontaneously hypertensive rat. *Experimental Cell Research*, Vol.241, No.1, pp. 186-193, ISSN 0014-4827.

Sin, A.Z., Roche, E.M., Togias, A., Lichtenstein, L.M. & Schroeder, J.T. (2001). Nerve growth factor or IL-3 induces more IL-13 production from basophils of allergic subjects than from basophils of nonallergic subjects. *Journal of Allergy and Clinical Immunology*, Vol.108, No.3, pp. 387-393, ISSN 0105-4538.

Skaper, S.D. (2008). The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. *CNS and Neurological Disorders Drug Targets*, Vol.7, No.1, pp. 46-62, ISSN 1871-5273.

Solomon, A., Aloe, L., Pe'er, J., Frucht-Pery, J., Bonini, S., Bonini, S. & Levi-Schaffer, F. (1998). Nerve growth factor is preformed in and activates human peripheral blood eosinophils. *Journal of Allergy and Clinical Immunology*, Vol.102, No.3, pp. 454-460, ISSN 0105-4538.

Stephens, R.M., Loeb, D.M., Copeland, T.D., Pawson, T., Greene, L.A. & Kaplan, D.R. (1994). Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses. *Neuron*, Vol.12, No.3, pp. 691-705, ISSN 0896-6273.

Susaki, Y., Shimizu, S., Katakura, K., Watanabe, N., Kawamoto, K., Matsumoto, M., Tsudzuki, M., Furusaka, T., Kitamura, Y. & Matsuda, H. (1996). Functional properties of murine macrophages promoted by nerve growth factor. *Blood*, Vol.88, No.12, pp. 4630-4637, ISSN 0006-4971.

Tacconelli, A., Farina, A.R., Cappabianca, L., Gulino, A. & Mackay, A.R. (2005). TrkAIII. A novel hypoxia-regulated alternative TrkA splice variant of potential physiological and pathological importance. *Cell Cycle*, Vol.4, No.1, pp. 8-9, ISSN 1538-4101.

Takahashi, H., Uno, S., Watanabe, Y., Arakawa, K. & Nakagawa, S. (2000). Expression of nerve growth factor-induced type 1 plasminogen activator inhibitor (PAI-1) mRNA is inhibited by genistein and wortmannin. *Neuroreport*, Vol.11, No.5, pp. 1111-1115, ISSN 0959-4965.

Takahashi, Y., Shimokawa, N., Esmaeili-Mahani, S., Morita, A., Masuda, H., Iwasaki, T., Tamura, J., Haglund, K. & Koibuchi, N. (2011). Ligand-induced downregulation of TrkA is partly regulated through ubiquitination by Cbl. *FEBS Letters*, Vol.585, No.12, pp. 1741-1747, ISSN 0014-5793.

Tam, S.Y., Tsai, M., Yamaguchi, M., Yano, K., Butterfield, J.H. & Galli, S.J. (1997). Expression of functional TrkA receptor tyrosine kinase in the HMC-1 human mast cell line and in human mast cells. *Blood*, Vol.90, No.5, pp. 1807-1820, ISSN 0006-4971.

Torcia, M., Bracci-Laudiero, L., Lucibello, M., Nencioni, L., Labardi, D., Rubartelli, A., Cozzolino, F., Aloe, L. & Garaci, E. (1996). Nerve growth factor is an autocrine survival factor for memory B lymphocytes. *Cell*, Vol.85, No.3, pp. 345-356, ISSN 0092-8674.

Ueda, K., Hirose, M., Murata, E., Takatori, M., Ueda, M., Ikeda, H. & Shigemi, K. (2010). Local administration of a synthetic cell-penetrating peptide antagonizing TrkA function suppresses inflammatory pain in rats. *Journal of Pharmacological Sciences*, Vol.112, No.4, pp. 438-443, ISSN 0022-3549.

Watson, J.J., Allen, S.J. & Dawbarn, D. (2008). Targeting nerve growth factor in pain: what is the therapeutic potential? *BioDrugs*, Vol.22, No.6, pp. 349-359, ISSN 1173-8804.

Weier, H.U., Rhein, A.P., Shadravan, F., Collins, C. & Polikoff, D. (1995). Rapid physical mapping of the human trk protooncogene (NTRK1) to human chromosome 1q21-q22 by P1 clone selection, fluorescence in situ hybridization (FISH), and computer-assisted microscopy. *Genomics*, Vol.26, No.2, pp. 390-393, ISSN 0888-7543.

Wiese, S., Digby, M.R., Gunnersen, J.M., Gotz, R., Pei, G., Holtmann, B., Lowenthal, J. & Sendtner, M. (1999). The anti-apoptotic protein ITA is essential for NGF-mediated survival of embryonic chick neurons. *Nature Neuroscience*, Vol.2, No.11, pp. 978-983, ISSN 1097-6256.

Wiesmann, C. & de Vos, A.M. (2001). Nerve growth factor: structure and function. *Cellular and Molecular Life Sciences*, Vol.58, No.5-6, pp. 748-759, ISSN 1420-682X.

Wilfong, E.R. & Dey, R.D. (2004). Nerve growth factor and substance P regulation in nasal sensory neurons after toluene diisocyanate exposure. *American Journal of Respiratory Cell and Molecular Biology*, Vol.30, No.6, pp. 793-800, ISSN 1044-1549.

Wilfong, E.R. & Dey, R.D. (2005). The release of nerve growth factor from the nasal mucosa following toluene diisocyanate. *Journal of Toxicology and Environmental Health. Part A*, Vol.68, No.15, pp. 1337-1348, ISSN 1528-7394.

Wooten, M.W., Zhou, G., Seibenhener, M.L. & Coleman, E.S. (1994). A role for zeta protein kinase C in nerve growth factor-induced differentiation of PC12 cells. *Cell Growth and Differentiation*, Vol.5, No.4, pp. 395-403, ISSN 1044-9523.

Wu, Z.X. & Dey, R.D. (2006). Nerve growth factor-enhanced airway responsiveness involves substance P in ferret intrinsic airway neurons. *American Journal of Physiology. Lung Cellular and Molecular Physiology*, Vol.291, No.1, pp. L111-118, ISSN 1040-0605.

Xu, M., Remillard, C.V., Sachs, B.D., Makino, A., Platoshyn, O., Yao, W., Dillmann, W.H., Akassoglou, K. & Yuan, J.X. (2008). p75 neurotrophin receptor regulates agonist-induced pulmonary vasoconstriction. *American Journal of Physiology. Heart and Circulatory Physiology*, Vol.295, No.4, pp. H1529-1538, ISSN 0363-6135.

Yamaguchi, Y., Katoh, H., Yasui, H., Mori, K. & Negishi, M. (2001). RhoA inhibits the nerve growth factor-induced Rac1 activation through Rho-associated kinase-dependent pathway. *Journal of Biological Chemistry*, Vol.276, No.22, pp. 18977-18983, ISSN 0021-9258.

York, R.D., Molliver, D.C., Grewal, S.S., Stenberg, P.E., McCleskey, E.W. & Stork, P.J. (2000). Role of phosphoinositide 3-kinase and endocytosis in nerve growth factor-induced extracellular signal-regulated kinase activation via Ras and Rap1. *Molecular and Cellular Biology*, Vol.20, No.21, pp. 8069-8083, ISSN 0270-7306.

Zweifel, L.S., Kuruvilla, R. & Ginty, D.D. (2005). Functions and mechanisms of retrograde neurotrophin signalling. *Nature Reviews. Neuroscience*, Vol.6, No.8, pp. 615-625, ISSN 1471-0048.



Inflammatory Diseases - A Modern Perspective
Edited by Dr. Amit Nagal

ISBN 978-953-307-444-3
Hard cover, 240 pages
Publisher InTech
Published online 16, December, 2011
Published in print edition December, 2011

"Inflammatory Diseases - A Modern Perspective" represents an extended and thoroughly revised collection of papers on inflammation. This book explores a wide range of topics relevant to inflammation and inflammatory diseases while its main objective is to help in understanding the molecular mechanism and a concrete review of inflammation. One of the interesting things about this book is its diversity in topics which include pharmacology, medicine, rational drug design, microbiology and biochemistry. Each topic focuses on inflammation and its related disease thus giving a unique platform which integrates all the useful information regarding inflammation.

INTECH
open science | open minds

InTech Europe
University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821